MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Leucine-rich repeat kinase 2(LRRK2)"

  • 2022 International Congress

    The influence of GBA and LRRK2 on mood disorders in Parkinson’s Disease

    A. Thaler, N. Omer, B. Cohen, N. Giladi, M. Kestenbaum, J. Shirvan, J. Cedarbaum, M. Gana-Weisz, O. Goldstein, A. Orr-Urtreger, A. Mirelman (Tel-Aviv, Israel)

    Objective: To assess the influence of mutations in the LRRK2 and GBA genes on mood disorders among patients with Parkinson's disease (PD) Background: Mood disorders…
  • 2022 International Congress

    Genetics Of Parkinson’s in India – Young Onset Parkinson’s Disease (GOPI-YOPD) : Genetics of Juvenile, Young and Early Onset Parkinson’s Disease

    P. Kukkle, V. Goyal, T. Geetha, R. Menon, R. Kandadai, U. Mahadevia, H. Kumar, R. Borgohain, A. Mukherjee, P. Wadia, R. Yadav, S. Desai, N. Kumar, S. Nair, S. Murugan, A. Biswas, P. Pal, M. Oliver, S. Sundaram, M. Deshmukh, A. Bassi, C. Sandeep, N. Mandloi, A. Kayalvizhi, U. Muthane, S. Das, S. Seshagiri, R. Gupta, V. Ramprasad (Bangalore, India)

    Objective: To determine the genetic and demographic patterns of juvenile-onset (JOPD, <20 years), young-onset (YOPD, 20-40 years), and early onset (EOPD, 40-50 years) Parkinson's disease…
  • MDS Virtual Congress 2021

    Increased stroke risk in Parkinson’s disease patients with LRRK2 mutations

    D. Macias-Garcia, MT. Periñán, L. Muñoz-Delgado, S. Jesús, MV. Jimenez-Jaraba, D. Buiza-Rueda, M. Bonilla-Toribio, A. Adarmes-Gomez, F. Carrillo, P. Gómez-Garré, P. Mir (Seville, Spain)

    Objective: To determine whether genetic forms of Parkinson’s Disease (PD), such as LRRK2-mutated PD (LRRK2-PD) and GBA­-mutated PD (GBA­-PD), have a different vascular risk compared…
  • MDS Virtual Congress 2021

    Familial Parkinson’s disease (PD) with anticipation phenomenon. Undescribed variant in the LRRK2 gene (c.4001G> A (p.Arg1334Gln))

    M. Mata, C. Jimeno (Madrid, Spain)

    Objective: We describe a family with 4 members affected by PD, carrying a new variant of the LRRK2 gen, with anticipation phenomenon in succeding generation.…
  • MDS Virtual Congress 2021

    Glucocerebrosidase activity does not predict Parkinson’s Disease risk or severity

    N. Omer, N. Giladi, T. Gurevich, A. Bar-Shira, M. Gana-Weisz, T. Glinka, O. Goldstein, M. Kestenbaum, J. Cedarbaum, O. Mabrouk, K. Fraser, J. Shrivan, A. Orr-Urtreger, A. Mirelman, A. Thaler (Tel-Aviv, Israel)

    Objective: To explore the association between GCase activity, PD phenotype and probability for prodromal PD among PD and non-manifesting carriers (NMC) of mutations in the…
  • MDS Virtual Congress 2021

    Investigating LRRK2 and GBA genetic variability in underrepresented populations

    C. Paisan-Ruiz, V. Katsnelson, N. Urval, R. Ortega, A. Debebe, I. Peter, S. Bressman, R. Saunders-Pullman (New York, USA)

    Objective: To address the pressing need through promoting collaborative translational work evaluating genetic signatures in Latinx and African-American (AA) participants with and without Parkinson’s disease…
  • MDS Virtual Congress 2021

    Reduced serum PRDX3 levels are a biomarker for Asian LRRK2 carriers in Parkinson’s disease

    YJ. Tan, ZH. Lu, EYL. Ng, SYE. Ng, NSY. Chia, ACW. Yong, XY. Choi, DD. Heng, S. Neo, ZY. Xu, KY. Tay, WL. Au, LCS. Tan, EK. Tan, ASL. Ng (Singapore, Singapore)

    Objective: We measured serum peroxiredoxin-3 (PRDX3) levels in Parkinson’s disease (PD) patients with and without LRRK2 risk variants, hypothesizing that PD LRRK2 carriers will show…
  • MDS Virtual Congress 2021

    Mutations in GBA and LRRK2 are not associated with increased inflammatory markers

    A. Thaler, N. Omer, N. Giladi, T. Gurevich, A. Bar Shira, O. Goldstein, M. Gana-Weisz, M. Kestenbaum, J. Shirvan, J. Cedarbaum, A. Orr-Urtreger, S. Shenhar-Tsarfaty, A. Mirelman (Tel-Aviv, Israel)

    Objective: To assess central and peripheral cytokines among Parkinson's disease (PD) patients with mutations in the LRRK2 and GBA genes as well as among non-manifesting…
  • MDS Virtual Congress 2021

    LIPAD (LRRK2/Luebeck) International Parkinson’s Disease Study: Protocol and feasibility study

    T. Usnich, EJ. Vollstedt, N. Schell, V. Skrahina, X. Bogdanovic, H. Gaber, T. Förster, A. Heuer, N. Koleva-Alazeh, I. Csoti, A. Nazli Basak, S. Ertan, G. Genc, P. Bauer, K. Lohmann, A. Grünewald, E. Schymanski, J. Trinh, S. Schaake, D. Berg, D. Gruber, S. Isaacson, A. Kühn, B. Mollenhauer, D. Pedrosa, K. Reetz, E. Sammler, EM. Valente, F. Valzania, J. Volkmann, S. Zittel, N. Brüggemann, M. Kasten, A. Rolfs, C. Klein (Lübeck, Germany)

    Objective: To systematically assess clinical signs and symptoms including non-motor features, comorbidities, medication and environmental factors in 1,000 participants internationally: 300 with LRRK2 (Leucine-rich repeat…
  • MDS Virtual Congress 2021

    Correlating LRRK2 activation status in peripheral blood to urine BMPs in monogenic and idiopathic Parkinson’s disease

    S. Gomes, A. Garrido, F. Tonelli, E. Tolosa, M. Marti, D. Anderson, N. Pratuseviciute, F. Hsieh, T. Bruecke, T. Koenig, C. Hotzy, J. Ruiz-Martínez, A. Bergareche-Yarza, E. Mondragón Rezola, A. Vinagre Aragón, I. Croitoru, A. Gorostidi Pagola, L. Paternain Markinez, F. Valldeoriola, K. Merchant, S. Padmanabhan, A. Zimprich, D. Alessi, E. Sammler (Dundee, United Kingdom)

    Objective: The greatest unmet need in Parkinson’s disease (PD) are disease-modifying treatments. The discovery of monogenic forms of PD has provided invaluable insights into pathomechanisms…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 16
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley